Qualix BV, Leuven, Belgium.
Int J Health Policy Manag. 2023;12:7470. doi: 10.34172/ijhpm.2023.7470. Epub 2023 Jul 10.
The increasing use in clinical practice of software such as mobile apps and clinical decision support (CDS) software has only recently been taken up by regulators around the world. Specifically, the European Commission and the US Food and Drug Administration (FDA) have updated their regulatory framework in the last years. Van Laere et al have given an extensive overview of the European and US approaches to regulate CDS software. This commentary further discusses regulatory differences between the two geographies and their impact on manufacturers of medical device software. We discuss the practical implementation of the regulatory framework for medical device software (especially CDS software) with a reference to the available international guidance documents and their limitations. Given the direction of stricter regulatory oversight in Europe, additional European guidelines/examples are desirable to enable a pragmatic regulatory approach ensuring continued access to innovative medical device software for European patients.
近年来,移动应用程序和临床决策支持 (CDS) 软件等软件在临床实践中的使用日益增多,这一现象才刚刚引起世界各地监管机构的关注。具体来说,欧盟委员会和美国食品药品监督管理局 (FDA) 在过去几年中更新了其监管框架。Van Laere 等人对欧洲和美国监管 CDS 软件的方法进行了全面概述。本评论进一步讨论了这两个地区之间的监管差异及其对医疗器械软件制造商的影响。我们讨论了医疗器械软件(特别是 CDS 软件)监管框架的实际实施情况,并参考了现有的国际指导文件及其局限性。考虑到欧洲加强监管监督的方向,需要制定更多的欧洲指南/示例,以实现一种务实的监管方法,确保欧洲患者能够继续获得创新的医疗器械软件。